Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Homerun Slides: Clinical presentation library Previous | All Articles This Week | Next
This article originally posted 02 July, 2012 and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2

DCMS91HS 

Part 1 of this two-part series covers some of the newest therapies for type 2 diabetes including GLP-1 agonists and DPP-4 inhibitors. We also take a look at some of the even newer therapies on the horizon such as SGLT2 inhibitors, ultra long-acting insulin (degludec) and interleukin-1 blocker, diacerein. 

Link to download (.ppt format): Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2.

Other sets in this series:

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2

Check out all of Diabetes In Control's slide collections at our Clinical Presentations Library.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 02 July, 2012 and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Past five issues: Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 | GLP-1 Special Editions August 2014 | Issue 742 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Statin Adherence Linked to New Onset Diabetes Risk
Posted July 25, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
HbA1c Increases with Age
Posted August 01, 2014
Connection between Type 1 Diabetes and Ulcerative Colitis?
Posted August 01, 2014
Regression from Prediabetes to Normal Glucose Reduces CVD Risk
Posted July 25, 2014
New Way to Regenerate Beta Cells in Type 1 Diabetes Patients
Posted August 08, 2014
Comparing Weekly Dulaglutide to Daily Liraglutide
Posted August 01, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you recommend SGLT-2 drugs for type 1 diabetes?



Search Articles On Diabetes In Control